BioMarin Stock Jumps After Settling Yuviwel Patent Fight With Ascendis
BioMarin and Ascendis end all Yuviwel patent fights. Ascendis will pay 20% on U.S. sales and 18% in the EU, Brazil, and South Korea until 2030.
/ 9 items
#BMRN↓
BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
BioMarin to Acquire Alesta for $275 Million, Gaining Potential First Oral Therapy for Rare Bone Disease HPP
BioMarin is buying Alesta for $275M to add ALE1, a potential first-in-class oral therapy for hypophosphatasia, expanding its rare disease pipeline.
BioMarin Plans FDA Submission After Positive VOXZOGO Hypochondroplasia Trial
BioMarin’s VOXZOGO improved growth in children with hypochondroplasia, showing strong trial results and good safety.
BioMarin Halts Voxzogo Phase 2 Trials in Turner Syndrome, SHOX Deficiency & ACAN Deficiency After SCFE Safety Events
BioMarin is discontinuing Phase 2 Voxzogo trials for Turner Syndrome, SHOX-deficiency and ACAN-deficiency after SCFE events in investigator-sponsored studies. Noonan syndrome and most ISS trials continue as planned.
Ascendis Pharma Scores FDA Approval for Yuviwel – Weekly Injection to Boost Growth in Achondroplasia
FDA approves Ascendis Pharma's Yuviwel, the first once-weekly injection to boost growth in children 2+ with achondroplasia. Launch expected Q2 2026.